Pharmacokinetics of Nalbuphine After Intravenous and Intranasal Administration in Infants

NCT03059511 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
51
Enrollment
OTHER
Sponsor class

Stopped We conclude that the doses we administered were safe, but too low. We plan to continue the study with higher doses (0.1 mg/kg iv and 0.2 mg/kg intranasal).

Conditions

Interventions

Sponsor

University Children's Hospital, Zurich